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Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal
cancer (CRC). Preclinical evidence suggests that the sequential administration of IRI and FU produces synergistic activity, although
their clinical use has not been fully optimised. We investigated the interaction between short-term exposure to SN-38, the active
metabolite of IRI, and prolonged exposure to FU in human CRC HT-29 cells and observed that the synergism of action between the
two agents can be increased by extending the time of cell exposure to FU and reducing the interval between administration of the
two agents. Based on these findings, we performed a phase I trial in 25 advanced CRC patients using a modified IRI/FU regimen as
first-line therapy and evaluated three dose levels of IRI (150–300mg/m
2) and two of continuous infusion of FU (800–1000mg/m
2)
in a 3-weekly schedule. The most severe grade III–IV toxicities were neutropoenia in four cycles and diarrhoea in three. One patient
achieved complete response (4%), 12 a partial response (48%), the overall response rate was 52% (720, 95% CI); seven of 25
patients had stable disease (28%), the overall disease control was 80% (716, 95% CI). This modified IRI/FU schedule is feasible and
exhibits potentially interesting clinical activity.
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Combination therapy with FU, IRI and oxaliplatin (l-OHP)
administered in two- or three-drug regimens is the mainstay of
treatment for advanced CRC (Venook, 2005; O’Neil and Goldberg,
2005). Indeed, regimens combining FU with IRI or l-OHP are
equally effective in terms of response rate and overall survival
(Tournigand et al, 2004) and represent the standard first-line
treatment in advanced CRC (O’Neil and Goldberg, 2005). Although
three combinations of IRI and FU (IFL, FOLFIRI and AIOþIRI)
have been evaluated in phase III studies (Saltz et al, 2000;
Douillard et al, 2000; Ko ¨hne et al, 2005), several other schedules
have been proposed (Venook, 2005; Atalay et al, 2003). However,
no randomised clinical trials have compared these different FU/IRI
schedules, so that we do not know whether one regimen is better
than others.
The most effective regimens combining FU and IRI were
designed on the basis of preclinical evidence suggesting that the
antiproliferative activity of the two agents is schedule-dependent
(Guichard et al, 1997; Guichard et al, 1998; Mullany et al, 1998).
Indeed, the administration of IRI before FU produced additive or
synergistic effects in all colon carcinoma cell lines tested (Guichard
et al, 1998; Mans et al, 1999), whereas both the exposure of cells to
FU before IRI and the simultaneous administration of both drugs
produced antagonistic or only additive activity, depending on the
colon tumour cell model (Mans et al, 1999). Similar findings were
also reported in vivo, in athymic mice xenografts of colon
carcinoma cells (Guichard et al, 1997).
Several combination regimens with FU and IRI have been
evaluated as first-line therapy for advanced CRC, achieving a
response rate of 30–50% and an overall survival of 14–20 months
(Venook, 2005; O’Neil and Goldberg, 2005). Interestingly, the most
commonly used schedules – that is the FOLFIRI and IFL regimens
– consist in the sequential administration of IRI followed by FU
bolus and/or continuous infusion (c.i.). However, considering
that the half-life of IRI is about 10h (Robert and Rivory, 1998),
both regimens also combine the two drugs simultaneously in a
weekly (IFL regimen) or bi-weekly (FOLFIRI regimen) schedule
(Douillard et al, 2000; Saltz et al, 2000). While there is no clinical
evidence to prove that the drug interactions observed in preclinical
models also occur in humans and may affect the effectiveness of
FU- and IRI-based chemotherapy, the results obtained in vitro
clearly indicate a schedule-dependency of the interaction between
the two agents and suggest the possibility of improving the efficacy
of the combination. We therefore looked more closely at the
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sdependency of the synergism between FU and SN-38, the active
metabolite of IRI, on the extent of cell exposure to FU and the
interval between the two drugs in human colon carcinoma
HT-29 cells and translated the findings obtained in vitro into
clinical experience, evaluating a modified IRI/FU regimen in a
phase I trial.
PATIENTS AND METHODS
Cell Cultures and Chemicals. HT-29 human colon carcinoma cells
were cultured in DMEM containing 10% foetal bovine serum,
glutamine and Penicillin/Streptomycin (Sigma-Aldrich, Italy)
(Khatib et al, 2001). SN-38 was kindly provided by Aventis Inc.,
Paris, France. Stock solution of SN-38 was prepared in DMSO at
10mM. FU was purchased from Sigma-Aldrich and diluted in
phosphate buffer saline. Either drugs or the same DMSO volume
were added to the cultures at the concentrations specified in the
Results; incubation was carried out continuously and fresh drug-
containing medium was changed at 24-h intervals.
The cell-cycle phase distribution and the rate of necrosis and
apoptosis were evaluated as previously reported (Landriscina et al,
2000; Sciamanna et al, 2005).
In order to select HT-29 colon carcinoma cells resistant to FU
(HT29 FUR) or to SN-38 (HT29 SN-38R), cells were continuously
incubated in the presence of increasing concentrations of FU and
SN-38 starting from 0.1nM for both drugs (Lesuffleur et al, 1991).
Cells were finally stabilised in the presence of 9mM FU and 100nM
SN-38. The resistance to each drug was assessed by MTT dye assay
(see below) and by measuring apoptosis in the presence of
increasing concentrations of FU or SN-38.
Immunoblot analysis and cytotoxicity assay
Immunoblot analysis was performed as previously reported
(Landriscina et al, 2000). Specific bands were revealed using a
mouse monoclonal anti-thymidylate synthase (TS) antibody
(Histoline Laboratories, Italy).
Growth inhibition by cytotoxic agents was measured using the
MTT (Sigma-Aldrich, Italy) dye assay as previously described
(Zeghari-Squalli et al, 1999). Briefly, 10
4 cells were seeded into 24-
well plates and incubated, 24h later, in the presence of increas-
ing concentrations of FU (10
 4 100mM) or SN-38 (10
 6 10mM)a s
specified in the Results. Three independent cytotoxicity assays
were used to calculate EC30 SN-38 and EC30 FU. Combination
assays were performed using EC30 SN-38 (0.11mM) or FU (5.2mM)
with increasing concentrations of FU or SN-38, respectively. SN-38
was always administered for 6h, whereas FU was administered for
24–96h, as specified in the Results. In the sequential schedule, the
second drug was administered immediately after the first drug or,
in some experiments, after an incubation of cells in a drug-free
medium for 24–96h. After the removal of both drugs, cells were
incubated in a drug-free medium for 72h and 50ml of a 125mM
MTT solution were then added to each well. The plates were
incubated for additional 3h at 371C to allow MTT metabolism into
formazan crystals. The formazan crystals were finally solubilised
by adding 200ml of 0.04N HCl in isopropanol to each microplate
well. Adsorbance at 540nm was measured using a Bio-Tek
microplate reader (model EL-340; BioMetallics, Priceston, NJ,
USA). Wells containing only DMEM, 10% FBS and MTT were used
as controls. Each experiment was performed at least three times,
using four replicates for each drug concentration.
Analysis of combination effects
Combination analysis was performed using the method described
by Chou et al. (Chou and Talalay, 1984; Chou et al, 1994). The
influence of the two drugs on the combination was evaluated by
comparing the sequential assay with assays involving the two
drugs simultaneously or alone. The combination effect was
evaluated from isoeffect analysis CIs, calculated as follows:
CI ¼ CFU=CxFUþCSN 38=CxSN 38
where CxFU and CxSN-38 are respectively the concentrations of FU
and SN-38 alone needed to achieve a given effect (x%) and CFU and
CSN-38 are the concentrations of the two drugs needed to obtain the
same effect when FU and SN-38 are combined. The CIs were
calculated under the assumption of a mutually exclusive drug
interaction. The combination was considered as positive (syner-
gistic) when the combination index was o1 and negative
(antagonistic) when it was 41.
Patients
Patients with locally advanced or metastatic CRC, histologically or
cytologically proven, were eligible for this study. Minimum age for
enrolment was 18 years. Other requisites of eligibility were disease
measurability according to RECIST criteria (Therasse et al, 2000);
PS (ECOG) 0–2; adequate organ function: white blood cell count
43000/ml, platelet count 4100000/ml, Hgb412g/dl, creatinine
o1.5mg/dl, total bilirubin o2mg/dl and transaminase levels o3
times upper normal limits. FU- and folinic acid (LFA)-based
adjuvant chemotherapy and prior surgery for primary tumour
were allowed. All patients were informed of the investigational
nature of the study and expressed written informed consent. The
study was approved by the local Ethics Committee.
Clinical study design
To translate the results of the preclinical part of this study, an
open-label, dose-escalating phase I trial was designed in which
groups of four to six patients were to receive increasing doses of
IRI and c.i. FU until dose-limiting toxicity (DLT) was demon-
strated in at least two of six patients. Four dose levels of IRI and
two of FU were evaluated in this study. We obtained five cohorts
of patients: (i) IRI 150mg/m
2 and FU 800mg/m
2 as a 4-day c.i.,
(ii) IRI 200mg/m
2 and FU 800mg/m
2 as a 4-day c.i., (iii) IRI
250mg/m
2 and FU 800mg/m
2 as a 4-day c.i., (iv) IRI 250mg/m
2
and FU 1000mg/m
2 as a 5-day c.i. and (v) IRI 300mg/m
2 and FU
1000mg/m
2 as a 5-day c.i. IRI was administered intravenously as
1h infusion, while FU was given starting 24h after IRI adminis-
tration by means of portable infusion pumps in an outpatient
setting. Cycles were repeated every 3 weeks until the maximum
number of 12 was reached.
Toxicity was evaluated according to NCI-CTC version 2. DLT
was defined as the occurrence of grade III nonhaematological
toxicity, except alopecia, asthaenia, nausea and vomiting, or grade
IV neutropoenia complicated by fever or lasting for more than 5
days, or grade IV thrombocytopoenia, or a delay of more than 2
weeks in treatment due to toxicity. A minimum of four patients
was observed for at least one complete cycle of combination
therapy before escalating to the next dose level. In the event that
fewer than two patients experienced DLT at the same dose level, a
minimum of four patients were entered at the next higher dose
level. All patients in the prior cohort were required to have
completed one cycle of therapy before enrolment in the next
cohort began. If two instances of DLT were observed at any dose
level, the maximum tolerated dose (MTD) was considered to have
been exceeded and a total of six patients were to be treated at the
previous dose level to confirm its tolerability.
Response was evaluated after four cycles according to RECIST
criteria and confirmed within 6 weeks. Patients received up to 12
cycles of chemotherapy provided they had stable disease, partial
or complete response. Treatment was interrupted in the event of
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sunacceptable toxicity, disease progression, patient refusal or
physician’s decision.
RESULTS
The synergism between SN-38 and FU in vitro depends on
the extent of cell exposure to FU and the interval between
administration of the two drugs
In preliminary experiments, we confirmed in human colon
carcinoma HT-29 cells the well known evidence that the synergism
between FU and SN-38 is schedule-dependent, with maximal
supra-additive effect when SN-38 is administered first (Guichard
et al, 1997; Guichard et al, 1998; Mullany et al, 1998). Cells were
therefore exposed to (i) SN-38 alone for 6h, FU alone for 24h, (ii)
the simultaneous combination of the two drugs (SN-38 and FU for
6h followed by FU for 18h) or (iii) both sequential combinations
of the two drugs (SN-38 for 6h and FU for 24h and vice versa).
The CI isobologram equation was used for the analysis of the
interaction between SN-38 and FU (Chou and Talalay, 1984; Chou
et al, 1994).
Figure 1A illustrates the results obtained after exposure of HT-
29 cells (i) to increasing concentrations of FU alone (10
 4 100mM)
or (ii) to the combination of EC30 SN-38 (0.11mM) and increasing
concentrations of FU using both sequences or after concomitant
exposure to EC30 SN-38 and increasing concentrations of FU.
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Figure 1 The schedule-dependent synergism between SN-38 and FU. (A) Cytotoxicity evaluated by MTT assay after exposure of human colon
carcinoma HT-29 cells to increasing concentrations of FU (10
 4 100mM) for 24h, the sequential combination of EC30 SN-38 (0.11mM) for 6h and
increasing concentrations of FU for 24h using both sequences and the concomitant treatment with EC30 SN-38 for 6h and increasing concentrations of FU
for 24h. (B) Cytotoxicity evaluated by MTT assay after exposure of HT-29 to increasing concentrations of SN-38 (10
 6 10mM) for 6h, the sequential
combination of EC30 FU (5.2mM) for 24h and increasing concentrations of SN-38 for 6h using both sequences and the concomitant treatment with EC30 FU
for 24h and increasing concentrations of SN-38 for 6h. (C) Plot of the CIs vs the cytotoxicity, calculated from data reported in (A,B), using the methods
described by Chou et al (20–21) and under the assumption of a mutually exclusive drug interaction. CI41, antagonism; CI¼1, additive effect; CIo1,
synergism. (D) Plot of the CIs vs the cytotoxicity calculated from MTT assay data of HT-29 cells exposed sequentially to SN-38 for 6h followed by FU for 24,
48, 72 and 96h. (E) Plot of the CIs vs the cytotoxicity calculated from MTT assay data of HT-29 cells exposed to SN-38 for 6h followed by FU for 24h after
an interval between the two drugs of 0, 24, 48, 72 and 96h during which cells were incubated in a drug-free medium. (F) Plot of the CIs vs the cytotoxicity
obtained from MTT assay data of HT-29, HT-29 SN-38R and HT-29 FUR cells exposed to the sequence of SN-38 followed by FU for 96h. Insert:
Thymidylate synthase (TS) protein expression in wild-type HT-29 (line 1), HT-29 SN-38R (line 2) and HT-29 FUR (line 3) cells.
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concentrations of SN-38 alone (10
 6 10mM), EC30 FU (5.2mM)
and increasing concentrations of SN-38 in both sequences or
concomitantly with EC30 FU and increasing concentrations of SN-
38. As reported in Figure 1C, the maximal synergism between FU
and SN-38 was achieved when SN-38 was administered before FU
(green line). However, a synergism of action was also observed
with the reverse sequence (red line), whereas only an additive
effect was found with the concomitant exposure of HT-29 cells to
both drugs (black line).
As in clinical experience IRI is always administered as a short
infusion, while FU is administered either by bolus or as c.i.
(Venook, 2005; O’Neil and Goldberg, 2005), we designed specific
experiments to evaluate the possibility of improving the synergism
between SN-38 and FU by prolonging the extent of cell exposure
to FU. We therefore evaluated the synergism between a brief
exposure (6h) to SN-38 followed by a longer exposure to FU (24–
96h). As reported in Figure 1D, the synergism between the two
drugs was increased by prolonging the exposure of cells to FU,
reaching the maximal activity when cells were exposed to FU for
96h (blue line).
In a third set of experiments (Figure 1E), HT-29 cells were
exposed to the sequence of SN-38 for 6h followed by FU for 24h,
but the second drug was added to the cell culture immediately after
(black line) or after an interval of 24 (red line), 48 (green line), 72
(blue line) or 96h (brown line) during which cells were incubated
in a drug-free medium. Interestingly, the synergism between SN-38
and FU was unchanged whether the drug-free interval between SN-
38 and FU was 24 or 48h. In contrast, when cells were exposed to
the sequence of SN-38 and FU with a drug-free interval of 72 or
96h in between, the combination of the two cytotoxic agents
obtained only additive effects.
The sequential combination of SN-38 and FU results in an
increase in apoptosis and S-phase of the cell cycle
HT-29 cells were treated with the two drugs alone or with the
combination of SN-38 and FU and evaluated for the rate of
apoptosis and necrosis and the cell cycle distribution. Cells treated
with increasing concentrations of SN-38 (0.001–1mM) and FU
(0.1–100mM) revealed a dose-dependent increase in apoptosis
which is maximal at 100nM SN-38 and 10mM FU (data not shown).
Cells were exposed to 10nM SN-38 or 1mM FU for 24h, the
combination of both drugs for 24h or sequentially exposed to both
drugs for 24h. The sequential exposure of cells to SN-38 before FU
elicited the maximal increase in apoptosis, while the reverse
sequence produced intermediate levels of apoptosis compared with
the simultaneous exposure (Table 1). Interestingly, when the cells
were sequentially exposed to the two agents with an incubation of
96h in a drug-free medium after SN-38, the rate of apoptosis was
significantly lower and was comparable to that observed with the
simultaneous exposure (Table 1).
The cell cycle distribution in HT-29 cells exposed to (i) 1mM FU
for 24h, (ii) 10nM SN-38 for 24h, (iii) the combination of both
drugs for 24h and (iv) the sequence of both drugs for 24h was
further evaluated. FU produced an arrest of cells in S-phase of the
cell cycle, whereas SN-38 produced an arrest in the G2-M phase
(Table 2). Interestingly, HT-29 colon carcinoma cells sequentially
exposed to SN-38 followed by FU exhibited a significantly higher
increase in the S-phase fraction with no arrest in the G2–M phase,
while HT-29 cells exposed sequentially to FU followed by SN-38
exhibited an arrest of the cell cycle in both S- and G2–M phases
with a magnitude similar to that produced by the single agents. In
contrast, cells simultaneously exposed to SN-38 and FU exhibited
an arrest of the cell cycle in the S-phase similar to that induced by
FU alone, but not in the G2–M phase (Table 2).
The synergism between SN-38 and FU is partially
conserved in colon carcinoma HT-29 cells resistant to FU
or SN-38
In order to evaluate whether the synergism between SN-38 and FU
is able to overcome resistance to the individual agents, we obtained
HT-29 cells resistant to SN-38 (HT-29 SN-38R) or FU (HT-29 FUR)
and evaluated the interaction between the two drugs in both cell
lines. HT-29 SN-38R and HT-29 FUR cells required concentrations
of SN-38 or FU about 10 times higher than wild-type HT-29 cells to
exhibit similar rates of cytotoxicity or apoptosis (data not shown).
Moreover, HT-29 FUR cells exhibited increased protein levels of
TS (Figure1D, inset), the molecular target of FU (van Triest et al,
1999), which is in agreement with the well known observation that
the upregulation of TS is responsible for resistance to FU (Wong
et al, 2001). The cytotoxicity of the sequence of SN-38 followed by
FU for 96h was evaluated in HT-29, HT-29 SN-38R and HT-29
FUR cells. In single agent-resistant cells the synergism between
SN-38 and FU was still observed, albeit with a magnitude lower
than that obtained in wild-type HT29 cells (Figure 1F).
Patient population, toxicity and clinical activity
Between January 2003 and December 2004 25 patients were
enrolled in the clinical study. Patients’ characteristics are listed
in Table 3, while toxicities are reported in Table 4. A total of 203
cycles was administered without observing treatment-related
deaths. We reported three DLTs, all of which were grade III
diarrhoea, in separate patients. The first patient at step 3 resumed
treatment at a dose of 75% after recovering from grade II nausea/
vomiting, while grade III diarrhoea occurred during the first cycle
and was not repeated after dose reduction. The second and the
third patients experienced grade III diarrhoea at the second and
fourth cycle, respectively, and resumed treatment at full doses with
no further grade III toxicities. As we did not observe a minimum of
two DLTs at the same dose level, the MTD was not reached. Grade
Table 1 Analysis of cell viability in human colon carcinoma HT-29 cells exposed to different combinations of SN-38 and FU
Control 10nM SN-38 1lM FU SN-38+FU SN-38-FU FU-SN-38 SN-38-96 h-FU
Viable cells 92.071.7 87.371.3 84.671.9 71.771.3 59.771.9 66.372.3 74.671.7
Apoptosis 6.870.8 11.970.7 13.170.5 26.570.9 38.970.5 31.970.7 23.971.5
Necrosis 1.270.1 0.870.4 2.370.3 1.871.1 1.470.3 1.870.5 1.570.7
Table 2 Cell cycle distribution of human colon carcinoma HT-29 cells
exposed to different combinations of SN-38 and FU
G0–G1 S G2–M
Control 62.870.8 27.070.9 10.271.0
10nM SN-38 42.871.1 31.571.4 25.770.9
1mM FU 45.971.4 44.171.6 10.070.7
10nM SN-38+1mM FU 40.971.6 46.070.7 13.171.3
10nM SN-38-1mM FU 37.271.4 60.871.9 2.070.2
1mM FU-10nM SN-38 34.571.1 45.472.3 20.171.2
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with G-CSF administration. Mucositis and gastrointestinal toxicity
(i.e. diarrhoea and nausea/vomiting) were the most relevant and
frequently observed grade I/II toxicities; they were generally mild
and rapidly reversible. The treatment was never interrupted due to
toxicity.
Efficacy data are summarised in Table 5. The most remarkable
result is 1 complete response, which lasted over 10 months. Twelve
patients achieved a partial response (48%). Stable disease was
observed in seven patients (28%), while progressive disease was
recorded in five patients (20%). Overall response and disease
control rates were 52% (720, 95% CI) and 80% (716, 95% CI),
respectively. Median time to progression was 7 months (range
2–11 months).
Three patients who had received adjuvant chemotherapy were
enrolled in this trial. The first had relapsed 2 months after the end
of adjuvant treatment, while the other two relapsed after 24 and
48 months, respectively. The first two patients were enrolled at
step 3 and the third at step 5 and, interestingly, all of them
achieved a partial response. The first two patients recorded a time
to further progression of 9 months, while the third, who also
Table 3 Baseline characteristics of the patients
Patients 25
Age
Range 35–79
Median 60
Sex
Female 7
Male 18
PS ECOG N%
01 9 7 6
15 2 0
21 4
Previous surgery
Resection/colectomy 18
Bypass 3
None 4
Adjuvant CT 5
Metastatic site N%
Liver 21 84.0
Lung 3 13.0
Nodes 3 13.0
Peritoneum 4 16.0
Other 2 8.7
Table 4 Adverse events in patients who received different dose levels of the combination of FU and IRI
Level 1 (27 cycles) Level 2 (29 cycles) Level 3 (45 cycles) Level 4 (55 cycles) Level 5 (47 cycles) Total (203 cycles)
Hematological
Anaemia
Grade I–II 0 0 0 1 (1.8%) 0 1 (0.5%)
Grade III–IV 0 0 0 0 0 0
Neutropoenia
Grade I–II 1 (3.7%) 0 0 0 0 1 (0.5%)
Grade III–IV 0 0 3 (6.6%) 1 (1.8%) 0 4 (2.0%)
Nonhaematological
Nausea/Vomiting
Grade I–II 3 (11.1%) 4 (13.8%) 10 (22.2%) 10 (18.2%) 9 (19.1%) 36 (17.7%)
Grade III–IV 0 0 0 1 (1.8%) 0 1 (0.5%)
Diarrhoea
Grade I–II 8 (29.6%) 6 (20.7%) 11 (24.4%) 7 (12.7%) 9 (19.1%) 41 (20.2%)
Grade III–IV 0 0 1 (2.2%) 1 (1.8%) 1 (2.1%) 3 (1.5%)
Stipsis
Grade I–II 0 0 0 4 (7.3%) 0 4 (2.0%)
Grade III–IV 0 0 0 0 0 0
Stomatitis
Grade I–II 1 (3.7%) 1 (3.4%) 9 (20.0%) 7 (12.7%) 2 (3.6%) 20 (9.8%)
Grade III–IV 0 0 0 0 0 0
Fatigue
Grade I–II 4 (14.8%) 1 (3.4%) 1 (2.2%) 2 (3.6%) 2 (3.6%) 10 (4.9%)
Grade III–IV 0 0 0 0 0 0
Flu-like syndrome
Grade I–II 1 (3.7%) 0 1 (2.2%) 1 (1.8%) 0 3 (1.5%)
Table 5 Overall and partial response rates in patients who received
different dose levels of the combination of FU and IRI
CR PR S PD
Step 1 0 0 2 2
Step 2 0 2 1 1
Step 3 0 4 0 1
Step 4 0 3 3 0
Step 5 1 3 1 1
Total 1 12 7 5
% 4 48 28 20
Response rate (%) 52
Disease control rate (%) 80
FU and IRI sequence in human colorectal cancer
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metastasis, was progression-free at the time of this statistical
analysis (11 months after the end of chemotherapy).
Most patients had a good PS at the end of treatment and all of
them received second-line treatment.
DISCUSSION
Over the past 10 years the treatment of advanced CRC has
progressed dramatically, with a shift from monotherapy to
combination therapy and, more recently, to sequential combina-
tion therapy (Venook, 2005; O’Neil and Goldberg, 2005; Kelly and
Goldberg, 2005). The introduction of IRI and l-OHP in the first-
and second-line setting has increased the complexity of delivery of
care to patients. Moreover, the recent development of molecular-
targeted agents that are tumour-specific and have different toxicity
profiles from chemotherapeutic agents has further widened the
range of therapies for this disease (Venook, 2005; O’Neil and
Goldberg, 2005). As these more efficacious agents allow patients
to survive longer and to receive more lines of therapy, issues have
arisen concerning the choice of the best schedule and the best
sequence of treatments. However, while most of the regimens
combining l-OHP and FU differ only marginally, the combinations
of IRI and FU are characterised by major differences in terms of
doses and schedules (Venook, 2005; O’Neil and Goldberg, 2005;
Tournigand et al, 2004; Saltz et al, 2000; Douillard et al, 2000).
In the present study we investigated, at preclinical level, the
interaction between FU and SN-38, the active metabolite of IRI, in
order to obtain in vitro evidence for optimising chemotherapeutic
schedules. We observed that (i) the sequential exposure of colon
carcinoma cells to the two agents produces a supra-additive effect
with maximal cytotoxic activity when cells are pre-exposed to SN-
38 before FU, (ii) this synergism of action is partially conserved in
colon carcinoma cells resistant to SN-38 or FU, and, interestingly,
(iii) it is possible to strengthen this synergism of action further
by prolonging the exposure of tumour cells to FU and by
administering the two agents sequentially with minimal interval
in between.
Other preclinical studies previously suggested that preincuba-
tion of colon carcinoma cells with IRI before FU enhances the
incorporation of FU derivatives into the DNA and DNA–protein
complexes with a parallel and more persistent decrease in TS
activity (Guichard et al, 1998). Furthermore, increased DNA
damage was also observed in SW620 and HT-29 colon carcinoma
cells when cells were pre-exposed to IRI before FU (Mans et al,
1999). These results are in agreement with our findings that the
sequential exposure of colon carcinoma cells to SN-38 before FU
produces a significant increase either in apoptosis or in the S-
phase arrest. Indeed, while FU produced an arrest of cells in S-
phase of the cell cycle and SN-38 produced an arrest in the phase
G2–M, as previously reported (Mullany et al, 1998; Yoshikawa
et al, 2001; McDonald and Brown, 1998), tumour cells sequentially
exposed to SN-38 followed by FU exhibited a significantly higher
increase in the S-phase fraction with no arrest in the G2–M phase.
Thus, it is likely that preincubation of colon carcinoma cells with
SN-38 facilitates in turn a more prolonged inhibition of TS by FU,
an increase in the incorporation of FU derivatives into DNA, an
enhanced and persistent S-phase arrest and apoptotic cell death.
This hypothetical mechanism of action provides a molecular
rationale to our results showing that the synergistic activity of the
SN-38 and FU sequence is partially conserved in colon carcinoma
cells resistant to FU and characterised by increased levels of TS. It
is also in agreement with the clinical observation that the FU- and
IRI-based combination therapy is effective in patients pretreated
with FU (Andre et al, 1999) and whose tumours are generally
characterised by increased levels of TS (Wong et al, 2001) as well
as with our results obtained in three patients previously treated
with FU-based adjuvant chemotherapy who achieved partial
response with this modified FU/IRI regimen. Furthermore, our
results suggest that IRI-resistant CRC cells may be more sensitive
to schedules with c.i. FU, although the molecular mechanism of
this synergism is still unclear.
The evidence that pre-incubation of HT-29 colon carcinoma
cells with FU before SN-38 achieves synergism of action is partially
in contrast with results reported by other authors, which suggest
that the sequential exposure of cells to FU before IRI produces only
additive activity (Mans et al, 1999). These differences may depend
on the specific colon tumour cell model used.
Based on these preclinical findings and considering the low
toxicity profile of infusional FU (Poplin et al, 2005), we designed a
modified IRI/FU schedule with IRI administered on day 1 followed
by a 4- or 5-day infusion of FU. We tested this alternative FU/IRI-
based regimen in a phase I trial, evaluating three dose levels of
IRI and two of FU in a 3-weekly schedule. Compared with the
commonly used two-drug regimens (Venook, 2005), our schedule
proved feasible and did not increase either haematological toxicity
or the rate of high-grade diarrhoea and stomatitis. This is even
more relevant in view of the toxicity profile of some traditional
combination regimens of IRI and FU (i.e. IFL) in which a large
proportion of patients experienced grade III–IV haematological
and nonhaematological toxicity (Saltz et al, 2000). Although the
MTD was not reached it is unlikely that this depends on the dose
levels of IRI and FU. Indeed, in our modified IRI/FU schedule
the theoretical weekly dose intensities of IRI and FU at the highest
dose levels are 90 and 1660mg/m
2, respectively, very similar to the
dose intensities of IRI and FU in the FOLFIRI and IFL regimens
(Saltz et al, 2000; Douillard et al, 2000). Thus, taking into account
that the rate of treatment delays or dose reductions reported in our
study is low, it is reasonable to speculate that, at least at the highest
dose levels, IRI and FU are not under-dosed.
Our regimen, tested as first-line treatment in 25 patients with
advanced CRC, obtained a response rate 450%, a disease control
rate of 80% and a time to progression of 7 months. These results
are promising even though they were achieved in a dose-escalating
phase I trial whose major aim was not to evaluate the antitumour
activity. Taking into account that at the first dose level, we did not
observe any response, probably because IRI was under-dosed,
these findings are even more significant. Indeed, if only patients
enrolled between the second and fifth dose levels are considered,
the overall response and disease control rates reached 61.9 and
85.7%, respectively. Similar results were recently achieved in a
phase I dose-escalating trial of IRI and c.i. FU as first-line
treatment of metastatic colorectal cancer. Interestingly, the
combination was well tolerated and demonstrated a significant
clinical activity, obtaining an overall response rate of 55%, a
clinical response benefit of 82% and a time to progression of 8
months (Saunders et al, 2004). Thus, the results of our study
clearly suggest that the schedule of administration of the two drugs
is critical to achieve the maximal supra-additive cytotoxic activity
and that the lack of full synergism in some traditional schedules
of IRI and FU may depend on the use of bolus FU (i.e. IFL) (Saltz
et al, 2000) and/or the need to optimise the sequence of
administration of the two agents (i.e. FOLFIRI) (Douillard et al,
2000).
Several options have been proposed to improve the efficacy of
standard two-drug regimens for advanced CRC (Venook, 2005).
Some studies have evaluated the combination of IRI, l-OHP and
FU concurrently in a single regimen, the rationale being that
nonspecific resistance to therapy may develop after first-line
therapy. Indeed, these studies demonstrated that three-drug
regimens achieve very high response rates (50–70%), but also
DLTs such as neutropoenia and diarrhoea (Souglakos et al, 2002;
Goetz et al, 2003). Other studies have evaluated the combination of
FU with l-OHP and/or IRI administered as chronomodulated
infusion. These trials also reported interesting response rates and
FU and IRI sequence in human colorectal cancer
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soptimal toxicity profiles, but raised questions about the feasibility
of chronomodulated chemotherapy (Garufi et al, 2003). However,
the analysis of seven phase III trials in advanced CRC suggested
that exposure to all three drugs, regardless of their sequence, is a
key element able to extend the overall survival of patients to 18–21
months (Grothey et al, 2004). Such a prospect strongly reinforces
the need to optimise doses and schedules of doublet chemother-
apy, in order to deliver the three drugs sequentially and obtain
maximal cytotoxic activity and minimal toxicity. Moreover, these
efforts seem even more relevant in the light of the introduction in
the clinical management of advanced CRC of new molecular-
targeted agents with a cytostatic mechanism of action requiring
precise timing when combined with traditional chemotherapeutic
drugs to maximise their efficacy (Venook, 2005). The combination
of IRI and cetuximab represents a salvage chemotherapy in IRI-
resistant patients (Venook, 2005), while the inclusion of bevaci-
zumab in IRI/FU combination has increased both response rates
and overall survival (Kelly and Goldberg, 2005). Optimising the
efficacy of a combination of IRI and FU could help to enhance the
overall efficacy of chemotherapy in CRC as first- or second-line
therapy. Thus, this modified IRI/FU regimen may represent a
precious alternative schedule with very low toxicity profile,
promising clinical activity and, therefore, worth being tested in a
larger phase II trial.
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